tirzepatide and mash fda Emerging Role of GLP-1 Receptor Agonists for the Treatment of MASH Tirzepatide in metabolic dysfunction-associated steatotic

TRIUMPH-1 included an overarching trial for adults with obesity and two nested basket trials, one of which focused on moderate-to-severe OSA

How Fella Health Compare Final Grade Average True Value Score Fella Health earns a C, held back by hidden pricing and checkout pressure tactics on what is otherwise a well-built clinic with strong coaching infrastructure

Unique advantage: Targets the source of desire rather than just the physical mechanics

Cardiovascular benefits: May reduce the risk of major adverse cardiovascular events (MACE)

Both compounds have half-lives around 5-8 days, so splitting by a few days does not change overall coverage much